Video

Dr. Frankfurt on the Future of AML Treatments

Author(s):

Olga Frankfurt, MD

Olga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.

Olga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.

Recent FDA-approved agents are being used in a variety of combinations and settings, explains Frankfurt. For example, a BCL-2 inhibitor is currently being studied in combination with hypomethylating agents, decitabine and azacitidine, as well as low-dose cytarabine to treat patients with AML.

PD-1 inhibitors are also being used in combinations to treat leukemia and myelodysplastic syndrome.

Related Videos
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
Related Content
Jorge E. Cortes, MD, of Georgia Cancer Center at Augusta University
May 31st 2024

Asciminib Bests Standard-of-Care TKIs in Ph+ CML

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Craig Eckfeldt, MD, PhD, of the University of Minnesota
May 22nd 2024

Eckfeldt Looks Towards the Future of AML and MDS Care

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

WU-CART-007 for R/R T-ALL and T-LBL| Image Credit: © Dr_Microbe - stock.adobe.com
May 20th 2024

WU-CART-007 Receives FDA RMAT and EMA PRIME Designations for R/R T-ALL and T-LBL

State of the Science Summit - Hematologic Malignancies: Chaired by Veronika Bachanova, MD, PhD, and Jeffrey Miller, MD
May 17th 2024

State of the Science Summit - Hematologic Malignancies: Chaired by Veronika Bachanova, MD, PhD, and Jeffrey Miller, MD